Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

ABSTRACT:

SUBMITTER: Costa LJ 

PROVIDER: S-EPMC10836587 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature